Read our editorial policy
Palatin Technologies has two additional MC4R agonists, PL-7737 which is an oral small molecule, and PL-8905 which is a synthetic peptide, both in preclinical development for obesity indications, with the former specifically targeting obesity caused by LEPR deficiency 15
Unless you advise to the contrary we will be free to copy, disclose, distribute, incorporate and otherwise use such material for any and all purposes
The T3 can't make its way into the receptor site because the receptor site is blocked
When uneven skin tone, dullness, or hyperpigmentation becomes more than just a cosmetic concern in a city like Chennai
Maged AM, Elsawah H, Abdelhafez A, Bakry A, Mostafa WA